-
Mashup Score: 6Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 16
Casirivimab/imdevimab protected uninfected contacts from COVID-19 and reduced symptomatic infections in trials before Omicron emerged.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 8Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 16Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 5Combination Casirivimab and Imdevimab and Development of Symptomatic COVID-19 in SARS-CoV-2 Infection - 2 year(s) ago
This randomized trial assesses the effect of a single dose of subcutaneous casirivimab and imdevimab antibody combination vs placebo on 28-day progression to symptomatic COVID-19 among asymptomatic SARS-CoV-2 reverse transcriptase–quantitative polymerase chain reaction–positive individuals living…
Source: jamanetwork.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 6
Among high-risk patients with mild to moderate COVID-19, casirivimab–imdevimab treatment was associated with a significantly lower rate of hospitalization.
Source: EClinicalMedicineCategories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0
Regeneron’s monoclonal antibodies, casirivimab and imdevimab (REGEN-COV), reduced risk of death by 20% in patients hospitalized with COVID-19 who had not mounted their own immune response.
Source: Contagion LiveCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 0Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 2Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 2Monoclonal antibody cocktail cut COVID-19 hospitalization, death by 70% in outpatient setting - 3 year(s) ago
A cocktail of two monoclonal antibodies — casirivimab and imdevimab — significantly reduced the risk for hospitalization or death in nonhospitalized patients with COVID-19, according to results of a phase 3 pivotal trial.Casirivimab with imdevimab (REGEN-COV, Regenerson) also shortened symptom duration and reduced viral load, researchers reported during a breaking news session at the
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
Presented at #ATS2021: Monoclonal antibody cocktail (REGEN-COV) of #casirivimab plus #imdevimab significantly hospitalization, death, symptom duration and viral load in non-hospitalized patients with #COVID19 @InfectDisNews https://t.co/yEyp8CNbVn
-
Study found treatment with subcutaneous #casirivimab and #imdevimab antibody combination compared with placebo significantly reduced the incidence of symptomatic #COVID19 among recently exposed, asymptomatic individuals. https://t.co/7Mk6V2ZMQc